Eesti - eesti - Ravimiamet

menarini international operations luxembourg s.a. - olmesartaanmedoksomiil - õhukese polümeerikattega tablett - 40mg 98tk; 40mg 14tk

Eesti - eesti - Ravimiamet

menarini international operations luxembourg s.a. - olmesartaanmedoksomiil+hüdroklorotiasiid - õhukese polümeerikattega tablett - 20mg+12,5mg 30tk; 20mg+12,5mg 10tk; 20mg+12,5mg 90tk; 20mg+12,5mg 98tk

Eesti - eesti - Ravimiamet

menarini international operations luxembourg s.a. - deksketoprofeen - suukaudse lahuse graanulid - 25mg 10tk; 25mg 100tk; 25mg 50tk; 25mg 500tk; 25mg 20tk; 25mg 40tk; 25mg 2tk

Eesti - eesti - Ravimiamet

menarini international operations luxembourg s.a. - olmesartaanmedoksomiil+amlodipiin+hüdroklorotiasiid - õhukese polümeerikattega tablett - 40mg+10mg+12,5mg 300tk; 40mg+10mg+12,5mg 90tk; 40mg+10mg+12,5mg 7tk; 40mg+10mg+12,5mg 28tk; 40mg+10mg+12,5mg 84tk; 40mg+10mg+12,5mg 14tk; 40mg+10mg+12,5mg 98tk; 40mg+10mg+12,5mg 500tk; 40mg+10mg+12,5mg 30tk; 40mg+10mg+12,5mg 280tk; 40mg+10mg+12,5mg 10tk

Eesti - eesti - Ravimiamet

menarini international operations luxembourg s.a. - tramadool+deksketoprofeen - suukaudse lahuse graanulid kotikeses - 75mg+25mg 100tk; 75mg+25mg 10tk; 75mg+25mg 500tk; 75mg+25mg 3tk; 75mg+25mg 15tk; 75mg+25mg 20tk; 75mg+25mg 2tk; 75mg+25mg 50tk

Eesti - eesti - Ravimiamet

menarini international operations luxembourg s.a. - deksketoprofeen - õhukese polümeerikattega tablett - 25mg 20tk; 25mg 4tk; 25mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - Ühenduse omandatud infektsioonid - antibacterials süsteemseks kasutamiseks, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 ja 5. tuleks arvesse võtta ametlikke juhiseid sobiva kasutada antibakteriaalseid aineid.

Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - trastuzumab - breast neoplasms; stomach neoplasms - antineoplastilised ained - breast cancermetastatic breast cancer zercepac is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. eelnev keemiaravi peab olema kantud vähemalt anthracycline ja taxane välja arvatud juhul, kui patsientidele ei sobi nende ravi. hormooni retseptori positiivne patsientidel peab olema ebaõnnestunud hormoonravi, välja arvatud juhul, kui patsientidele ei sobi nende ravi.                      in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. koos docetaxel raviks nendel patsientidel, kes ei ole saanud keemiaravi oma metastaatilise haiguse. kombinatsioonis aromataasi inhibiitoriga ravi postmenopausis patsientidel hormoon-retseptor positiivne mbc, mis ei ole varem ravitud trastuzumab. early breast cancer zercepac is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc). pärast operatsiooni, kemoteraapiat (neoadjuvant-või abiaine) ja kiiritusravi (kui on kohaldatav). järgmised abiaine keemiaravi koos doxorubicin ja tsüklofosfamiidiga kombinatsioonis paclitaxel või docetaxel. koos abiaine keemiaravi, mis koosneb docetaxel ja carboplatin. in combination with neoadjuvant chemotherapy followed by adjuvant zercepac therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter. zercepac should only be used in patients with metastatic or early breast cancer whose tumours have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay. metastatic gastric cancer zercepac in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with her2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. zercepac should only be used in patients with metastatic gastric cancer (mgc) whose tumours have her2 overexpression as defined by ihc2+ and a confirmatory sish or fish result, or by an ihc 3+ result. täpseid ja valideeritud analüüsi meetodeid tuleks kasutada.

Eesti - eesti - Ravimiamet

menarini international operations luxembourg s.a. - deksketoprofeen - graanulid kotikeses - 25mg 20tk; 25mg 4tk; 25mg 500tk; 25mg 100tk; 25mg 50tk; 25mg 30tk; 25mg 10tk; 25mg 2tk

Eesti - eesti - Ravimiamet

menarini international operations luxembourg s.a. - bilastiin - suus dispergeeruv tablett - 20mg 50tk; 20mg 10tk; 20mg 40tk